Report

QuickView: To the victor the spoils...but not quite yet

Forward Pharma has been designated the senior party in the US Patent Trial and Appeal Board (PTAB) interference proceedings between Forward's '871 patent application and Biogen's '514 patent, based on its earlier filing date. The average time to interference resolution is ~13 months (excluding appeals) and investors will see the legal arguments filed in July and September 2015. If Forward Pharma prevails, damages awarded could be significant.
Underlying
Forward Pharma ADS

Provider
Edison Investment Research
Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

.

Other Reports on these Companies
Other Reports from Edison Investment Research

ResearchPool Subscriptions

Get the most out of your insights

Get in touch